TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18491071
Drug: Lean fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lean fish (150 g cod, three times/week)
Study: 18491071
Drug: Fatty fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fatty fish (150 g salmon, three times/week)
Study: 12970007
Drug: Nebulized levalbuterol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized levalbuterol, 1.25 mg
Study: 12970007
Drug: Racemic albuterol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Racemic albuterol, 2.5 mg
Study: 12970007
Drug: Combined racemic
Normalized name: EPINEPHRINE,RACEMIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined racemic albuterol, 2.5 mg, and ipratropium, 0.5 mg
Study: 8678103
Drug: Cefepime (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime (1 g every 12 hours)
Study: 8678103
Drug: Ceftazidime (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime (1 g every 8 hours)
Study: 1906097
Drug: Cefixime (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime (8 mg/kg daily)
Study: 1906097
Drug: Amoxicillin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (40 mg/kg daily)
Study: 24458078
Drug: Ferumoxytol (1.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferumoxytol (1.02 g, 2 × 510‐mg injections)
Study: 24458078
Drug: Iron sucrose
Normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron sucrose (1.0 g, administered as slow injection or infusion)
Study: 10325782
Drug: Terbutaline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline infusion
Study: 2019314
Drug: 2 or
Normalized name: CP-2 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 or 3 mg/kg diazoxide given 2.5 min before laryngoscopy
Study: 6765414
Drug: Standard amikacin
Normalized name: Amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard amikacin dosing (15 mg/kg per day in four divided doses) with ticarcillin or piperacillin
Study: 6765414
Drug: Pharmacokinetically adjusted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacokinetically adjusted amikacin dosing (mean dosage of 29.4 mg/kg per day) with ticarcillin or moxalactam
Study: 6765414
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (previous amikacin-plus-ticarcillin trial with 15 mg/kg per day)
Study: 25985046
Drug: Double-blinded fluoxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-blinded fluoxetine for 8 months
Study: 25985046
Drug: Pill placebo
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pill placebo for 8 months
Study: 25985046
Drug: Continuation-phase treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuation-phase treatments (CT, fluoxetine, placebo)
Study: 24001030
Drug: ECA (Embodied
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECA (Embodied Conversational Agent)
Study: 24001030
Drug: ECA (Embodied
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECA (Embodied Conversational Agent) for participants with adequate health literacy
Study: 19061808
Drug: Mini-implants for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mini-implants for en-masse retraction (G1)
Study: 17718288
Drug: Cinnamon cassia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnamon cassia powder 1.5 g/d
Study: 9283507
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy added to group drug counseling
Study: 9283507
Drug: Supportive-expressive psychodynamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive-expressive psychodynamic therapy added to group drug counseling
Study: 9283507
Drug: Individual drug
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual drug counseling added to group drug counseling
Study: 11680559
Drug: Group drug
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group drug counseling alone
Study: 8393895
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg oral d-fenfluramine
Study: 14636813
Drug: Skinfolds and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skinfolds and combination of methods
Study: 11776204
Drug: LHRH‐a (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: LHRH‐a (150 micrograms/d, i.m.) plus norethindrone (2.5 mg/d, p.o.)
Study: 8634919
Drug: Oral hydralazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hydralazine (75 mg qid)
Study: 1631944
Drug: MALG (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: MALG (20 mg/kg/day)
Study: 1631944
Drug: OKT3 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: OKT3 (5 mg/day)
Study: 24849445
Drug: 20% mannitol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% mannitol (2 ml/kg, infused for over 20 min)
Study: 24849445
Drug: 15% hypertonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15% hypertonic saline (0.42 ml/kg, administered as a bolus via a central venous catheter)
Study: 20395226
Drug: Atorvastatin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin + N-acetylcysteine (NAC)
Study: 20395226
Drug: Atorvastatin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin + NAC
Study: 12794414
Drug: Dexamethasone, 1
Normalized name: Dexamethasone, 1 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone, 1 mg/kg iv (group II, n = 15)
Study: 28605472
Drug: ACT +
Normalized name: sodium fluoride Mouthwash [ACT Fluoride Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT + primaquine (0.25 mg/kg)
Study: 10912897
Drug: salbutamol (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: salbutamol (4 mg)
Study: 1330880
Drug: Azithromycin 1000
Normalized name: azithromycin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 1000 mg single dose
Study: 6695766
Drug: Prazosin added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin added to propranolol (reduced to 120 mg/day)
Study: 6695766
Drug: Prazosin added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin added after tapering and discontinuing propranolol
Study: 23090620
Drug: Capecitabine tablet
Normalized name: Capecitabine Tablets
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine tablet formulation (500 mg)
Study: 23090620
Drug: Control formulation
Normalized name: nut.tx, weight loss-control formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control formulation of capecitabine (500 mg)
Study: 19120715
Drug: Valsartan 320
Normalized name: valsartan 320 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 320 mg/d
Study: 19120715
Drug: Hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ) 25 mg/d
Study: 19120715
Drug: Valsartan/HCTZ 320/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan/HCTZ 320/25 mg/d
Study: 16357487
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) treatment, n=62
Study: 16357487
Drug: Baseline food
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline food intake before GH treatment
Study: 16296712
Drug: Diltiazem (30‐60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (30‐60 mg three times daily)
Study: 30503386
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg of testosterone cypionate
Study: 27374668
Drug: Repaglinide (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repaglinide (0.25 or 0.5 mg just before breakfast and dinner twice daily)
Study: 27374668
Drug: Repaglinide (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repaglinide (0.25 or 0.5 mg just before meals thrice daily)
Study: 27374668
Drug: Sulfonylurea (continuing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfonylurea (continuing treatment)
Study: 23483320
Drug: parecoxib sodium
Normalized name: parecoxib sodium
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: parecoxib sodium (40 mg) intravenously (IV) at the completion of surgery and once every 12 h for a total of 6 times postoperatively
Study: 23483320
Drug: placebo (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (normal saline 2 mL IV at the same time points)
Study: 19463203
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate nasal spray (FFNS), 110 microg
Study: 17223551
Drug: Serum 25(OH)D
Normalized name: 1α,25(OH)2D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum 25(OH)D levels in the second tertile (range 5.5‐66.1 ng/ml)
Study: 15088221
Drug: Social support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social support treatments targeting appropriate use of the health care system
Study: 12195181
Drug: Pelvic floor
Normalized name: Tenscare Kegel Toner Pelvic Floor Trainer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic floor exercises and biofeedback treatment
Study: 2406169
Drug: Home-visiting system
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home-visiting system with one or two weekly visits by domiciliary midwives
Study: 396653
Drug: Pirenzepine (PRZ)
Normalized name: pirenzepine
DrugBank: Pirenzepine (DB00670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine (PRZ) 75 mg/day for 1 week followed by 50 mg/day for 3 weeks
Study: 396653
Drug: Pirenzepine (PRZ)
Normalized name: pirenzepine
DrugBank: Pirenzepine (DB00670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine (PRZ) 100 mg/day for 4 weeks
Study: 396653
Drug: Carbenoxolone (CB)
Normalized name: carbenoxolone
DrugBank: Carbenoxolone (DB02329)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbenoxolone (CB) 300 mg/day for 1 week followed by 200 mg/day for 3 weeks
Study: 23053618
Drug: Immediate CAMP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate CAMP treatment (n = 15)
Study: 23053618
Drug: Waitlist (delayed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waitlist (delayed treatment; n = 14)
Study: 8863869
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIG) infusions 1 g kg‐1 (n = 23)
Study: 8863869
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone pulse therapy (MPPT) 30 mg kg‐1 (n = 20)
Study: 8863869
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone pulse therapy (MPPT)
Study: 1480736
Drug: HAL DIRS‐C
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAL DIRS‐C (Drug Impairment Rating Scale for Cocaine) administered weekly
Study: 27766596
Drug: Both acupuncture
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both acupuncture treatments
Study: 24217938
Drug: Oral metformin
Normalized name: metformin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral metformin (1,500 mg to 2,000 mg daily)
Study: 24217938
Drug: Increased insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Increased insulin dose (control group)
Study: 21083860
Drug: Oral metformin
Normalized name: metformin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral metformin
Study: 20364382
Drug: Cytoreductive nephrectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoreductive nephrectomy and cytokine therapy
Study: 16847636
Drug: Tamoxifen citrate
Normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen citrate (TMX) at a 20-mg dosage
Study: 16847636
Drug: No ovulation-induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: No ovulation-induction drugs (Control)
Study: 12787038
Drug: Systemic corticosteroid
Normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic corticosteroid therapy with prednisone (50 mg/day) followed by clobetasol ointment plus antimycotics
Study: 12787038
Drug: Topical treatment
Normalized name: Hongo Killer Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatment with clobetasol plus antimycotics
Study: 11068775
Drug: Daily ATG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily ATG (DATG)
Study: 3069682
Drug: Labetalol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (200 mg twice a day)
Study: 6094076
Drug: Hydrochlorothiazide (HCTZ),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ), 25 mg twice a day (group 1; n = 12)
Study: 6094076
Drug: Enalapril, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril, 10 mg twice a day (group 2; n = 12)
Study: 6094076
Drug: Enalapril, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril, 10 mg twice a day, with HCTZ, 25 mg twice a day (group 3; n = 5)
Study: 24534142
Drug: Budesonide 9
Normalized name: budesonide 9 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 9 mg once daily (OD)
Study: 24534142
Drug: Budesonide 3
Normalized name: budesonide 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 3 mg three times daily (TID)
Study: 24534142
Drug: Budesonide 9
Normalized name: budesonide 9 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 9 mg OD
Study: 24534142
Drug: Budesonide 3
Normalized name: budesonide 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 3 mg TID
Study: 17387132
Drug: Tilarginine (1‐mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tilarginine (1‐mg/kg bolus and 1‐mg/kg per hour 5‐hour infusion)
Study: 16229112
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of fluoxetine hydrochloride (20 mg dispersible tablet)
Study: 16229112
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of fluoxetine hydrochloride (20 mg dispersible tablet)
Study: 11603414
Drug: Human polyvalent
Normalized name: Human polyvalent shedded antigen vaccine
DrugBank: Seviprotimut-L (DB16328)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human polyvalent immunoglobulin for intravenous administration
Study: 11603414
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of immunoglobulin and plasmapheresis
Study: 8890204
Drug: CVD 1203
Normalized name: Vibrio cholerae CVD 103-HGR strain live antigen Oral Suspension [Vaxchora]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVD 1203 vaccine (1.5 x 10^8 CFU)
Study: 8890204
Drug: CVD 1203
Normalized name: Vibrio cholerae CVD 103-HGR strain live antigen Oral Suspension [Vaxchora]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVD 1203 vaccine (1.5 x 10^9 CFU)
Study: 8890204
Drug: CVD 1203
Normalized name: Vibrio cholerae CVD 103-HGR strain live antigen Oral Suspension [Vaxchora]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVD 1203 vaccine (1.2 x 10^6 CFU)
Study: 8890204
Drug: CVD 1203
Normalized name: Vibrio cholerae CVD 103-HGR strain live antigen Oral Suspension [Vaxchora]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVD 1203 vaccine
Study: 30618054
Drug: AZD4831 135
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD4831 135 mg
Study: 30618054
Drug: AZD4831 405
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD4831 405 mg
Study: 30618054
Drug: AZD4831 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD4831 (all doses)
Study: 22497598
Drug: Ribosomal prophylaxis
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribosomal prophylaxis with Immucytal® (one tablet daily, 8 days a month for 3 months)
Study: 17126918
Drug: Placebo (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (same dosage for the same period)
Study: 10527226
Drug: Rocuronium 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 1.0 mg/kg
Study: 7902034
Drug: Succinylcholine 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine 1.0 mg/kg
Study: 2186020
Drug: Clonazepam (0.5-2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonazepam (0.5-2.0 mg/day)
Study: 2186020
Drug: Imipramine (25-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (25-50 mg/day)
Study: 31713469
Drug: Carbapenem long-lasting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbapenem long-lasting (4h) infusion
Study: 27755109
Drug: Sorafenib treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib treatment
Study: 28052588
Drug: Sirukumab 50
Normalized name: Sirukumab
DrugBank: Sirukumab (DB11803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirukumab 50 mg by Prefilled Syringe‐UltraSafe Passive® Delivery System (PFS‐U)
Study: 28052588
Drug: Sirukumab 100
Normalized name: Sirukumab
DrugBank: Sirukumab (DB11803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirukumab 100 mg by Prefilled Syringe‐UltraSafe Passive® Delivery System (PFS‐U)
Study: 28052588
Drug: Sirukumab 50
Normalized name: Sirukumab
DrugBank: Sirukumab (DB11803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirukumab 50 mg by Prefilled Syringe‐SmartJect® Autoinjector (PFS‐AI)
Study: 28052588
Drug: Sirukumab 100
Normalized name: Sirukumab
DrugBank: Sirukumab (DB11803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirukumab 100 mg by Prefilled Syringe‐SmartJect® Autoinjector (PFS‐AI)
Study: 28052588
Drug: Sirukumab 100
Normalized name: Sirukumab
DrugBank: Sirukumab (DB11803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirukumab 100 mg intravenous (IV) infusion
Study: 28052588
Drug: Sirukumab 100
Normalized name: Sirukumab
DrugBank: Sirukumab (DB11803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirukumab 100 mg by PFS‐AI
Study: 11713920
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of atropine sulfate
Study: 7904003
Drug: Intranasal spray
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal spray
Study: 2923763
Drug: Cisapride 10
Normalized name: cisapride 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 10 mg i.v. in 5% dextrose 20 ml
Study: 786352
Drug: Practolol (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Practolol (120 mg)
Study: 23320650
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulphate (4930 mg = 20 mmol magnesium) administered 60 min before and 6 hours after ERCP
Study: 23320650
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered 60 min before and 6 hours after ERCP
Study: 17890730
Drug: Low-dose INR
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose INR self-management
Study: 15481562
Drug: Low-intensity home-based
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity home-based physical therapy (once a week for 10 weeks)
Study: 11853284
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid (Hyalgan 2 ml/wk for 4 doses)
Study: 11853284
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 ml of normal saline)
Study: 9763324
Drug: Electric toothbrush
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Electric toothbrush (Braun/Oral-B Ultra Plaque Remover-D9)
Study: 9763324
Drug: Electric toothbrush
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Electric toothbrush (Braun/Oral-B Plaque Remover-D7)
Study: 9763324
Drug: Electric toothbrush
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Electric toothbrush (Braun/Oral-B Ultra Plaque Remover-D9) with different types of endrounding
Study: 9763324
Drug: Electric toothbrush
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Electric toothbrush (Braun/Oral-B D7 at 2800 rot/min) and D9 at 3600 rot/min
Study: 7825006
Drug: Oral or
Normalized name: Doral Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral or intravenous rehydration (Control)
Study: 3254767
Drug: Oral high-frequency
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral high-frequency oscillation (OHFO) at 8 Hz
Study: 3254767
Drug: Oral high-frequency
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral high-frequency oscillation (OHFO) at 16 Hz
Study: 3254767
Drug: Oral high-frequency
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral high-frequency oscillation (OHFO) at 8 Hz, 12 Hz, and 16 Hz
Study: 31462117
Drug: Oral Tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tramadol 50 mg, 1 hour prior to the procedure
Study: 23640072
Drug: AZD1446 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD1446 80 mg qd
Study: 23640072
Drug: AZD1446 (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD1446 (80 mg tid, 80 mg qd, 10 mg tid)
Study: 12699447
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone (5 mg/day, n = 10)
Study: 31900204
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of lopinavir/ritonavir and recombinant interferon-Î²1b with standard supportive care
Study: 23610239
Drug: Aliskiren 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren 2 mg/kg
Study: 23610239
Drug: Aliskiren 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren 6 mg/kg
Study: 21362527
Drug: Coping skills
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coping skills training (CST) intervention: 16 weekly 30-minute telephone counseling sessions including motivational interviewing and individually tailored cognitive behavioral therapy.
Study: 21362527
Drug: Heart failure
Normalized name: INVESTIGATIONAL CONGESTIVE HEART FAILURE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heart failure education (HFE) intervention: 16 weekly 30-minute telephone sessions including education and symptom monitoring.
Study: 18204042
Drug: Hypoglycaemia (nadir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoglycaemia (nadir P-glucose 2.7 +/- 0.5 mmol/L)